MX371202B - Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética. - Google Patents

Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética.

Info

Publication number
MX371202B
MX371202B MX2016006620A MX2016006620A MX371202B MX 371202 B MX371202 B MX 371202B MX 2016006620 A MX2016006620 A MX 2016006620A MX 2016006620 A MX2016006620 A MX 2016006620A MX 371202 B MX371202 B MX 371202B
Authority
MX
Mexico
Prior art keywords
cell receptor
cell receptors
affinity human
engineered high
seq
Prior art date
Application number
MX2016006620A
Other languages
English (en)
Spanish (es)
Other versions
MX2016006620A (es
Inventor
M Schmitt Thomas
D Greenberg Philip
N Smith Sheena
M Kranz David
t harris Daniel
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of MX2016006620A publication Critical patent/MX2016006620A/es
Publication of MX371202B publication Critical patent/MX371202B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2016006620A 2013-11-22 2014-11-21 Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética. MX371202B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361907887P 2013-11-22 2013-11-22
PCT/US2014/066903 WO2015077615A1 (en) 2013-11-22 2014-11-21 Engineered high-affinity human t cell receptors

Publications (2)

Publication Number Publication Date
MX2016006620A MX2016006620A (es) 2017-05-11
MX371202B true MX371202B (es) 2020-01-22

Family

ID=53180203

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016006620A MX371202B (es) 2013-11-22 2014-11-21 Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética.
MX2016006625A MX383471B (es) 2013-11-22 2014-11-21 Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética.
MX2021006932A MX2021006932A (es) 2013-11-22 2016-05-20 Receptores de celulas t humanas con alta afinidad modificados por medio de manipulacion genetica.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2016006625A MX383471B (es) 2013-11-22 2014-11-21 Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética.
MX2021006932A MX2021006932A (es) 2013-11-22 2016-05-20 Receptores de celulas t humanas con alta afinidad modificados por medio de manipulacion genetica.

Country Status (20)

Country Link
US (4) US10344075B2 (https=)
EP (2) EP3071594A4 (https=)
JP (4) JP6476182B2 (https=)
KR (2) KR20160085345A (https=)
CN (2) CN105899530B (https=)
AU (4) AU2014352826B2 (https=)
BR (1) BR112016011567A2 (https=)
CA (2) CA2930847A1 (https=)
DK (1) DK3071593T3 (https=)
ES (1) ES2729406T3 (https=)
IL (2) IL245468B (https=)
MX (3) MX371202B (https=)
PL (1) PL3071593T3 (https=)
PT (1) PT3071593T (https=)
RU (2) RU2740648C2 (https=)
SA (1) SA516371174B1 (https=)
SG (2) SG10201804330YA (https=)
TR (1) TR201908404T4 (https=)
WO (2) WO2015077615A1 (https=)
ZA (2) ZA201603116B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2542141T3 (es) 2005-10-17 2015-07-31 Sloan Kettering Institute For Cancer Research Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
PL2010209T3 (pl) 2006-04-10 2017-04-28 Sloan Kettering Inst For Cancer Res Immunogeniczne peptydy WT-1 i sposoby ich użycia
CA2861206C (en) 2012-01-13 2021-07-06 Richard J. O'reilly Immunogenic wt-1 peptides and methods of use thereof
EP3769782A1 (en) 2013-01-15 2021-01-27 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
EP3071594A4 (en) * 2013-11-22 2017-05-03 The Board of Trustees of the University of Illionis Engineered high-affinity human t cell receptors
EP4706680A3 (en) * 2015-09-22 2026-03-25 Julius-Maximilians-Universität Würzburg A method for high level and stable gene transfer in lymphocytes
CA2998270A1 (en) 2015-10-01 2017-04-06 Ospedale San Raffaele S.R.L. Tcr and uses thereof
GB201520570D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
US11026969B2 (en) 2015-12-23 2021-06-08 Fred Hutchinson Cancer Research Center High affinity T cell receptors and uses thereof
MA45491A (fr) * 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
EP3538113A4 (en) 2016-11-14 2020-08-19 Fred Hutchinson Cancer Research Center HIGH AFFINITY MERKEL CELL POLYOMAVIRUS T ANTIGEN SPECIFIC TCRs AND THEIR USES
MX2019010972A (es) * 2017-03-15 2019-12-02 Hutchinson Fred Cancer Res Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos.
WO2018197492A1 (en) * 2017-04-24 2018-11-01 Ospedale San Raffaele S.R.L. Tcr and peptides
JP7181517B2 (ja) * 2018-01-23 2022-12-01 国立大学法人三重大学 Ｔ細胞レセプター
AU2019312200B2 (en) * 2018-07-23 2024-11-14 Heidelberg Pharma Research Gmbh Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy
CN113784978B (zh) 2019-03-11 2025-07-25 弗雷德哈钦森癌症中心 高亲合力wt1 t细胞受体及其用途
GB201911066D0 (en) 2019-08-02 2019-09-18 Achilles Therapeutics Ltd T cell therapy
JP7737978B2 (ja) * 2019-08-20 2025-09-11 フレッド ハッチンソン キャンサー センター Ｗｔ－１に特異的なｔ細胞免疫療法
JP2023513706A (ja) * 2020-02-12 2023-04-03 アッヴィ・インコーポレイテッド 二特異性結合分子
WO2021219990A1 (en) 2020-04-28 2021-11-04 Achilles Therapeutics Uk Limited T cell therapy
CN112239495B (zh) * 2020-10-29 2022-04-12 上海药明生物技术有限公司 稳定的tcr结构及应用
EP4320435A1 (en) 2021-04-09 2024-02-14 Achilles Therapeutics UK Limited Batch release assay for pharmaceutical products relating to t cell therapies
GB202109886D0 (en) 2021-07-08 2021-08-25 Achilles Therapeutics Uk Ltd Assay
WO2022269250A1 (en) 2021-06-22 2022-12-29 Achilles Therapeutics Uk Limited A method for producing antigen-specific t cells
CN117957012A (zh) * 2021-07-19 2024-04-30 得克萨斯州大学系统董事会 靶向fanci、rad51和pbk抗原的肽和经改造t细胞受体及使用方法
CN119220425A (zh) * 2023-07-28 2024-12-31 佳吾益(北京)科技有限公司 发现mhc新抗原肽表位的工程化细胞

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3927193A (en) 1973-05-18 1975-12-16 Hoffmann La Roche Localization of tumors by radiolabelled antibodies
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4361544A (en) 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4468457A (en) 1981-06-01 1984-08-28 David M. Goldenberg Method for producing a CSAp tryptic peptide and anti-CSAp antibodies
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4640561A (en) 1985-11-15 1987-02-03 Ford Motor Company Flexible printed circuit connector
US5059413A (en) 1988-04-18 1991-10-22 Xoma Corporation Scintigraphic monitoring of immunotoxins using radionuclides and heterobifunctional chelators
CA2065299C (en) 1989-08-09 2001-07-24 Buck A. Rhodes Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5299253A (en) 1992-04-10 1994-03-29 Akzo N.V. Alignment system to overlay abdominal computer aided tomography and magnetic resonance anatomy with single photon emission tomography
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
WO1999060120A2 (en) 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
ES2293748T3 (es) 1998-10-21 2008-03-16 Altor Bioscience Corporation Moleculas de fijacion poliespecificas y usos de las mismas.
AU2002321581C1 (en) * 2001-08-31 2008-09-18 Adaptimmune Limited Soluble T cell receptor
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
GB0328363D0 (en) * 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
NZ550815A (en) 2004-05-19 2009-04-30 Immunocore Ltd Method of improving T cell receptors
DK1765860T3 (da) 2004-05-19 2009-03-09 Immunocore Ltd Ny-ESO-T.cellereceptor med höj affinitet
GB0524477D0 (en) 2005-11-30 2006-01-11 Avidex Ltd Isolated T cell receptors which specifically bind to vygfvracl-hla-24
GB0511124D0 (en) 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
US9281917B2 (en) 2007-01-03 2016-03-08 Nokia Technologies Oy Shared control channel structure
CN102272153B (zh) * 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
WO2010075417A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
WO2010089412A1 (en) 2009-02-09 2010-08-12 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
CA2777053A1 (en) * 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
EA201390011A1 (ru) * 2010-07-28 2013-07-30 Иммьюнокор Лтд. Т-клеточные рецепторы
ES2635335T3 (es) * 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
SG10201609210SA (en) 2012-05-03 2016-12-29 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
WO2014191465A1 (en) * 2013-05-28 2014-12-04 Møller Niels Iversen Peptides derived from lawsonia intracellularis and their use in vaccination
PL228457B1 (pl) 2013-08-30 2018-03-30 Univ Jagiellonski Tomograf hybrydowy TOF-PET/CT
EP3071594A4 (en) 2013-11-22 2017-05-03 The Board of Trustees of the University of Illionis Engineered high-affinity human t cell receptors
CN107074970B (zh) 2014-08-04 2021-07-30 弗雷德哈钦森癌症研究中心 特异性针对wt-1的t细胞免疫疗法
CN110950964B (zh) * 2018-09-26 2021-06-18 安源医药科技（上海）有限公司 突变型单链人凝血因子viii融合蛋白及其制备方法与用途

Also Published As

Publication number Publication date
WO2015077607A1 (en) 2015-05-28
JP2017501130A (ja) 2017-01-12
CA2930847A1 (en) 2015-05-28
IL245468A0 (en) 2016-06-30
WO2015077615A1 (en) 2015-05-28
ES2729406T3 (es) 2019-11-04
IL245468B (en) 2020-10-29
CA2930852C (en) 2024-01-23
MX2016006625A (es) 2016-12-02
IL245467B (en) 2020-04-30
SG10201804330YA (en) 2018-07-30
NZ719707A (en) 2020-09-25
RU2729383C2 (ru) 2020-08-06
SA516371174B1 (ar) 2019-04-14
BR112016011567A2 (pt) 2017-10-24
JP2020007374A (ja) 2020-01-16
BR112016011583A2 (pt) 2017-09-26
JP6970724B2 (ja) 2021-11-24
JP2022023196A (ja) 2022-02-07
US20190055298A1 (en) 2019-02-21
RU2016124179A (ru) 2017-12-27
MX2016006620A (es) 2017-05-11
US20220396606A1 (en) 2022-12-15
IL245467A0 (en) 2016-06-30
US20160280756A1 (en) 2016-09-29
PT3071593T (pt) 2019-06-27
JP6476182B2 (ja) 2019-02-27
JP2017501129A (ja) 2017-01-12
AU2019272003A1 (en) 2019-12-19
CN105873945B (zh) 2020-07-17
KR20160085345A (ko) 2016-07-15
AU2014352834B2 (en) 2019-08-29
NZ719720A (en) 2020-09-25
CN105899530B (zh) 2020-05-08
JP6697386B2 (ja) 2020-05-20
EP3071593A4 (en) 2017-05-03
US10344075B2 (en) 2019-07-09
US20160280755A1 (en) 2016-09-29
EP3071593B1 (en) 2019-03-13
US10023625B2 (en) 2018-07-17
AU2014352834A1 (en) 2016-05-26
EP3071593A1 (en) 2016-09-28
MX2021006932A (es) 2021-07-07
KR20160087866A (ko) 2016-07-22
SG10201804335QA (en) 2018-06-28
RU2740648C2 (ru) 2021-01-19
AU2014352826A1 (en) 2016-05-26
MX383471B (es) 2025-03-14
ZA201603116B (en) 2018-12-19
KR102415259B1 (ko) 2022-06-30
EP3071594A1 (en) 2016-09-28
CA2930852A1 (en) 2015-05-28
RU2016124163A (ru) 2017-12-27
CN105873945A (zh) 2016-08-17
CN105899530A (zh) 2016-08-24
ZA201603169B (en) 2020-05-27
EP3071594A4 (en) 2017-05-03
PL3071593T3 (pl) 2019-11-29
AU2014352826B2 (en) 2019-08-01
AU2019272003B2 (en) 2021-05-06
AU2021202274A1 (en) 2021-05-06
DK3071593T3 (da) 2019-06-11
TR201908404T4 (tr) 2019-07-22

Similar Documents

Publication Publication Date Title
MX371202B (es) Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética.
CY1122539T1 (el) Αναλογα γλυκαγονης
EA201992536A1 (ru) Tcr и пептиды
CY1121462T1 (el) Ακυλιωμενα αναλογα γλυκαγονης
NZ715038A (en) T cell receptors
MX2017004559A (es) Receptores de celulas t.
EA201792245A1 (ru) Биоконъюгаты и их применения
MX377716B (es) Moduladores de aplnr y usos de estos.
UA118167C2 (uk) Пептид та його застосування
EA201590294A1 (ru) Аналоги глюкагона
MX2017000083A (es) Compuestos de platino, composiciones y usos de estos.
EA201500802A1 (ru) Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы
PE20141271A1 (es) Anticuerpos tipo receptor de celulas t especificos para un peptido wt1 presentado por hla-a2
EA201490070A1 (ru) Коантагонисты глюкагонового рецептора/glp-1-рецептора
BR112017016336A2 (pt) proteínas de ligação icos agonistas?
CL2012002095A1 (es) Polipéptido de unión biparatópico que comprende un primer dominio variable individual de inmunoglobulina (ig) que se une específicamente a un primer epítopo del péptido ß-amiloide (ßa) y un segundo dominio variable de ig que se une específicamente a un segundo epítopo del ßa, donde dichos epítopos del ßa no son idénticos; ácido nucleico que lo codifica; vector; célula hospedera; composición farmacéutica; método de preparación; y su uso en el tratamiento y/o prevención de depósitos del ßa
ECSP12012351A (es) Análogos de glucagón
GT201700224A (es) Proteína de unión a rgma y su uso
MX371403B (es) Moleculas de andamiaje a base de fibronectina estabilizada.
EA201492068A1 (ru) Гидрохлоридная соль пептида и ее применение в комбинации с другими пептидами в иммунотерапии
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
NZ706884A (en) Fc gamma receptor iib variants
GB201118201D0 (en) Novel peptides
MY193807A (en) T-cell receptor and uses thereof
SI3030259T1 (en) Peptides

Legal Events

Date Code Title Description
FG Grant or registration